Outcomes following HDR Brachytherapy Boost for High Risk Localised Prostate Cancer: Data from a UK Centre

被引：0
|
作者：
Lorimer, C. [1 ]
Ravi, B. [1 ]
Cowtan, F. [1 ]
Johns, A. [1 ]
Robinson, A. [1 ]
Nikapota, A. [1 ]
机构：
[1] Univ Hosp Sussex NHS Trust, Brighton, England
来源：
CLINICAL ONCOLOGY | 2023年 / 35卷 / 02期
关键词：
DOSE-RATE BRACHYTHERAPY; INTERMEDIATE; MONOTHERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E241 / E241
页数：1
相关论文
共 50 条
  • [41] HDR brachytherapy as boost combined with external radiotherapy for localised prostate cancer. Long term follow-up compared to nomogram
    Ryberg, M.
    Kalkner, K.
    Cohn-Cedermark, G.
    Castellanos, E.
    Zimmerman, R.
    Levitt, S.
    Nilsson, J.
    Holmberg, C.
    Lundell, M.
    Nilsson, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 240 - 240
  • [42] Image Guided HDR Brachytherapy Boost for Locally Advanced Prostate Cancer using Oncentra Prostate HDR Planning System
    Challapalli, A.
    Robinson, A.
    Dunn, P.
    Hellawell, G.
    Jones, E.
    Harvey, C.
    Mangar, S.
    CLINICAL ONCOLOGY, 2011, 23 (03) : S14 - S14
  • [43] Early outcomes in intensity modulated radiotherapy (IMRT) and high dose rate (HDR) brachytherapy boost for prostate cancer: A single institution experience
    Yong, J.
    Looi, W. S.
    Huang, H. H.
    Yuen, J.
    Tan, T.
    Tuan, J.
    Lau, W.
    BJU INTERNATIONAL, 2018, 122 : 13 - 13
  • [44] Patient-reported outcomes following a high-dose rate brachytherapy boost for prostate cancer.
    Parry, M.
    Nossiter, J.
    Cowling, T.
    Sujenthiran, A.
    Berry, B.
    Cathcart, P.
    Clarke, N.
    Payne, N.
    Van der Meulen, J.
    Aggarwal, A.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S621 - S621
  • [45] Single Fraction HDR Boost and Dose Escalation for Intermediate and High Risk Prostate Cancer. A Report of Toxicity from a Single Centre Experience
    Arthur, C.
    Mandall, P.
    Swindell, R.
    Logue, J. P.
    Wylie, J. P.
    CLINICAL ONCOLOGY, 2012, 24 (02) : 154 - 154
  • [46] Dose escalation with HDR brachytherapy for intermediate- and high-risk prostate cancer
    Chicas-Sett, R.
    Celada, F.
    Burgos, J.
    Farga, D.
    Perez-Calatayud, M.
    Roldan, S.
    Collado, E.
    Ibanez, B.
    Perez-Calatayud, J.
    Tormo, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S380 - S381
  • [47] HDR brachytherapy as monotherapy for low and intermediate risk prostate cancer
    Gaudet, M.
    Pharand-Charbonneau, M.
    Wright, D.
    Desrosiers, M.
    Haddad, A.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S1188 - S1188
  • [48] Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer
    Groom, Nicki
    Tsang, Yatman
    Lowe, Gerry
    Hoskin, Peter
    BRACHYTHERAPY, 2021, 20 (02) : 302 - 306
  • [49] HIGH DOSE-RATE BRACHYTHERAPY MONOTHERAPY (HDR-M) VERSUS BOOST (HDR-B) IN INTERMEDIATE RISK PROSTATE CANCER: PROPENSITY SCORE MATCHED ANALYSIS OF CANADIAN DATA
    Alrashidi, Saad
    Loblaw, Andrew
    Chung, Hans T.
    Tseng, Chia-Lin
    Ravi, Ananth
    Zhang, Liying
    Morton, Gerrard
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S40 - S40
  • [50] A single centre experience of HDR brachytherapy as salvage treatment for relapsed prostate cancer
    Dugdale, E.
    Slevin, F.
    Rodda, S.
    Bottomley, D.
    Carey, B.
    Smith, J.
    Hulson, O.
    Adiotomre, E.
    Mason, J.
    Bownes, P.
    Henry, A.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1249 - S1250
12345